2 February 2012 - Swedish Diamyd Medical (STO:DIAM B) said today that the New England Journal of Medicine (NEJM) had published an article with the findings of its European Phase III trial of the antigen-based diabetes therapy Diamyd.

The now published results were previously presented at th...

 

 

 

You must be logged in to view the whole article.
Click here if you require signing up